Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.

We have previously shown that the curative efficacy of low dose melphalan (L-phenylalanine mustard; L-PAM) for mice bearing a large s.c. MOPC-315 tumor requires the participation of CD8+ (but not CD4+) T cell-dependent antitumor immunity. Here we show that CD8+ T cells obtained from regressing tumors on day 4 or 5 after low dose L-PAM therapy of MOPC-315 tumor bearers (L-PAM TuB mice) display a preferential enhancement in the utilization of the TCR-V beta 8.3 gene segment as compared to CD8+ T cells from normal lymph nodes. Treatment of L-PAM TuB mice with mAb F23.1, which leads to the depletion of V beta 8.3+ cells, as well as V beta 8.1 and 8.2+ cells, led to a significant reduction in the ability of their tumor-infiltrating lymphocytes as well as their spleen cells to lyse MOPC-315 tumor cells in vitro in a short term assay. In addition, the mAb F23.1 treatment almost completely abrogated the lytic activity of the tumor-infiltrating lymphocytes against another syngeneic, antigenically related plasmacytoma (the MOPC-104E). Moreover, the mAb F23.1 treatment significantly reduced the curative effectiveness of low dose L-PAM for mice bearing a large MOPC-315 tumor. In contrast, mAb KJ16 treatment, which leads to the depletion of V beta 8.1 and 8.2+ cells (but not V beta 8.3+ cells), did not reduce significantly the curative effectiveness of low dose L-PAM for such MOPC-315 tumor bearers. Thus, V beta 8.3+ T cells are important for the curative effectiveness of low dose L-PAM therapy for MOPC-315 tumor bearers, and it is conceivable that the V beta 8.3+ cells mediate their effect (at least in part) by contributing to the acquisition of CTL activity against plasmacytoma-shared Ag.

• Publication year

  1993

• Venue

  Journal of Immunology

• Publication date

  1993-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.4049/jimmunol.151.9.4838PMID 8409442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers

  2004cited by this paper
• Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth

  2004cited by this paper
• Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models

  2004cited by this paper
• Differential effects of BCNU on T cell, macrophage, natural killer and lymphokine-activated killer cell activities in mice bearing a syngeneic tumor

  2004cited by this paper
• Expansion of murine T cells bearing a unique T cell receptor beta-chain in Friend virus-induced tumor in situ.

  1992cited by this paper
• The T cell receptor repertoire influences V beta element usage in response to myoglobin

  1991cited by this paper
• In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.

  1991cited by this paper
• Phenotypic characterization of murine tumor-infiltrating T lymphocytes.

  1991cited by this paper
• Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma.

  1990cited by this paper
• Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.

  1990cited by this paper
• Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.

  1990cited by this paper
• Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

  1990cited by this paper
• Relative V beta transcript levels in thymus and peripheral lymphoid tissues from various mouse strains. Inverse correlation of I-E and Mls expression with relative abundance of several V beta transcripts in peripheral lymphoid tissues

  1989cited by this paper
• The in vivo depletion of V beta 17a+ T cells results in the inhibition of reticulum cell sarcoma growth in SJL/J mice. Evidence for the use of anticlonotypic antibody therapy in the control of malignancy.

  1989cited by this paper
• Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.

  1989cited by this paper
• Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.

  1989cited by this paper
• Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.

  1989cited by this paper
• T cell receptor gene segment usage in a panel of hen-egg white lysozyme specific, I-Ak-restricted T helper hybridomas.

  1989cited by this paper
• The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype

  1988cited by this paper
• Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

  1988cited by this paper
• Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy.

  1988cited by this paper
• Possible role of V beta T cell receptor genes in susceptibility to collagen-induced arthritis in mice

  1988cited by this paper
• Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex

  1988cited by this paper
• Generation of diversity in T cell receptor repertoire specific for pigeon cytochrome c

  1987cited by this paper
• T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity [published erratum appears in J Exp Med 1986 Dec 1;164(6):2131]

  1986cited by this paper
• Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor.

  1985cited by this paper
• Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma.

  1985cited by this paper
• Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors

  1979cited by this paper
• Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

  1973cited by this paper
• Immunoglobulin-producing tumors and myeloma proteins of mice.

  1972cited by this paper

• Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor

  2006cites this paper
• Inhibition of Tumor-Eradicating Immunity Importance of IL-10 for CTLA-4-Mediated and

  2004cites this paper
• Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity1

  2004cites this paper
• Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.

  2001cites this paper
• Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing

  2000cites this paper
• B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells

  2000cites this paper
• Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors

  1999cites this paper
• Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487).

  1999cites this paper
• Large MOPC-315 Tumor Tumor-Eradicating Immunity by Mice Bearing a Melphalan-Induced Acquisition of Importance of the B 7-2 Molecule for Low Dose

  1998influential citation
• Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.

  1998cites this paper
• Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor

  1998cites this paper
• Experimental plasmacytomagenesis in mice.

  1997cites this paper
• T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden

  1997cites this paper
• Cell-mediated immune system regulation in periodontal diseases.

  1997cites this paper
• Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets

  1997cites this paper
• Decreased Expression and Function of Vß6+ and Vß14+ T Cells is Associated with Decreased Th1 Cytokine Production in Mice with Plasma Cell Tumors

  1996cites this paper
• Immunopharmacology of Anticancer Agents

  1996cites this paper
• Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.

  1996cites this paper
• Naive CD4+ T cells confer idiotype‐specific tumor resistance in the absence of antibodies

  1995cites this paper
• Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome

  1995cites this paper
• Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor β by treatment with bleomycin

  1995cites this paper
• Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.

  1995cites this paper
• Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy

  1994cites this paper
• Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.

  1994cites this paper
• Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.

  1994cites this paper
• Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.

  1994cites this paper
• Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor

  1994cites this paper